Schonfeld Strategic Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.33M | Sell |
4,576,152
-3,636,841
| -44% | -$3.44M | 0.03% | 548 |
|
|
2025
Q1 | $3.78M | Buy |
8,212,993
+654,372
| +9% | +$302K | 0.02% | 553 |
|
|
2024
Q4 | $5.58M | Buy |
7,558,621
+5,676,021
| +301% | +$4.19M | 0.03% | 436 |
|
|
2024
Q3 | $2.96M | Buy |
1,882,600
+1,311,108
| +229% | +$2.06M | 0.02% | 615 |
|
|
2024
Q2 | $3.24M | Sell |
571,492
-388,658
| -40% | -$2.2M | 0.02% | 602 |
|
|
2024
Q1 | $5.35M | Buy |
+960,150
| New | +$5.35M | 0.04% | 522 |
|
|
2023
Q4 | – | Sell |
-469,666
| Closed | -$512K | – | 1929 |
|
|
2023
Q3 | $512K | Sell |
469,666
-23,476
| -5% | -$25.6K | ﹤0.01% | 1076 |
|
|
2023
Q2 | $1.13M | Buy |
493,142
+334,142
| +210% | +$765K | 0.01% | 924 |
|
|
2023
Q1 | $386K | Buy |
159,000
+42,000
| +36% | +$102K | ﹤0.01% | 1251 |
|
|
2022
Q4 | $223K | Buy |
+117,000
| New | +$223K | ﹤0.01% | 1915 |
|
|
2021
Q1 | – | Sell |
-75,700
| Closed | -$259K | – | 1937 |
|
|
2020
Q4 | $259K | Buy |
+75,700
| New | +$259K | ﹤0.01% | 1215 |
|
|
2017
Q4 | – | Sell |
-15,781
| Closed | -$194K | – | 798 |
|
|
2017
Q3 | $194K | Buy |
+15,781
| New | +$194K | 0.02% | 520 |
|
|
2017
Q2 | – | Sell |
-10,000
| Closed | -$143K | – | 684 |
|
|
2017
Q1 | $143K | Buy |
+10,000
| New | +$143K | 0.01% | 559 |
|